Technical Analysis for PRVB - Provention Bio, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Historical PRVB trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Volume Surge | Other | 0.00% | |
| Calm After Storm | Range Contraction | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Stochastic Reached Oversold | Weakness | 0.00% | |
| BB Squeeze Ended | Range Expansion | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Fell Below 50 DMA | Bearish | -3.23% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| Trending on StockTwits | 1 day ago | |
| Trending on StockTwits | 2 days ago | |
| Down 5% | 2 days ago | |
| 5x Volume Pace | 2 days ago | |
| 60 Minute Opening Range Breakdown | 2 days ago |
Free Daily (Stock) Chart Reading
- Earnings date: 11/05/2020
Provention Bio, Inc. Description
Provention Bio, Inc. is a clinical-stage biopharmaceutical company that develops therapeutics targeting immune-mediated diseases. The Company aims at developing therapies for disease that include type one diabetes (T1D), Crohn’s disease, ulcerative colitis, lupus and other viral diseases. The Company’s principal product candidates include PRV-031, PRV-6527, PRV-300, PRV-3279, and PRV-0101.PRV-031 is a product candidate in its Phase III clinical trial that is developed for the interception of T1D. PRV-6527 is an oral CSF-1R inhibitor for the treatment of Crohn’s disease. PRV-300 is developed for the treatment of ulcerative colitis. PRV-3279 is developed to treat lupus disease. PRV-101 is a multivalent coxsackie virus (CVB) vaccine for the prevention of acute CVB and the prevention of the onset of T1D.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Immunology Disease Diabetes Autoimmune Diseases Ulcer Colitis Ulcerative Colitis Diarrhea Lupus Abdominal Pain Crohn's Disease Viral Disease Viral Diseases Immune Mediated Diseases
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 20.05 |
| 52 Week Low | 4.72 |
| Average Volume | 729,807 |
| 200-Day Moving Average | 13.64 |
| 50-Day Moving Average | 16.26 |
| 20-Day Moving Average | 17.45 |
| 10-Day Moving Average | 17.31 |
| Average True Range | 1.29 |
| ADX | 21.28 |
| +DI | 18.32 |
| -DI | 23.92 |
| Chandelier Exit (Long, 3 ATRs ) | 16.19 |
| Chandelier Exit (Short, 3 ATRs ) | 18.53 |
| Upper Bollinger Band | 19.32 |
| Lower Bollinger Band | 15.58 |
| Percent B (%b) | -0.15 |
| BandWidth | 21.45 |
| MACD Line | 0.00 |
| MACD Signal Line | 0.37 |
| MACD Histogram | -0.365 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 16.82 | ||||
| Resistance 3 (R3) | 16.92 | 16.40 | 16.52 | ||
| Resistance 2 (R2) | 16.40 | 15.94 | 16.36 | 16.42 | |
| Resistance 1 (R1) | 15.70 | 15.65 | 15.45 | 15.61 | 16.32 |
| Pivot Point | 15.19 | 15.19 | 15.06 | 15.14 | 15.19 |
| Support 1 (S1) | 14.49 | 14.72 | 14.23 | 14.39 | 13.68 |
| Support 2 (S2) | 13.97 | 14.44 | 13.92 | 13.58 | |
| Support 3 (S3) | 13.27 | 13.97 | 13.48 | ||
| Support 4 (S4) | 13.18 |
